Imatinib (Gleevec) as a Paradigm of Targeted Cancer Therapies

Home | About | Credits | Seminar List | Poster | Feedback

Imatinib (Gleevec) as a Paradigm of Targeted Cancer Therapies
Brian Druker, March 2007
HHMI / Oregon Health & Science University Cancer Institute

Lecture Overview
Although the majority of patients with CML respond well to imatinib, a minority of patients have relapsed. This part of the lecture will cover what has been learned about mechanisms of relapse and how this information has been translated into new therapies for patients with imatinib resistance. Although imatinib is a relatively specific inhibitor of the ABL kinase, a couple of other kinases, KIT and the platelet derived growth factor receptor are also inhibited by imatinib. This use of this information to treat successfully treat other malignant diseases driven by these kinases will be reviewed.
Part 2: Imatinib Resistance and Other Diseases
Targeted by Imatinib (25:12)

Click image above to start seminar in 320x240 format
Click here to view in larger 640x480 format*
QuickTime 7 Required    *640x480 System Requirements
(there may be a few seconds delay before seminars start)

Downloads in alternative formats:
(To Save, Right Click a link below and select "Save Target/Link As")
QuickTime (46mb)     MP4 (294mb)     iPod/iPhone Video (294mb)
PowerPoint Slides 1/page (681kb)     PowerPoint Slides 6/page (281kb)

Format Descriptions
Download Accelerator/Resume Broken Downloads Software

Part 1: Chronic Myeloid Leukemia (CML) and Imatinib (33:54)

Part 3: Extending the Imatinib Paradigm (22:09)

Speaker Bio    Related Articles

Disclaimers, Trademarks, & Terms of Use
© 2008 The American Society for Cell Biology
8120 Woodmont Avenue Suite 750, Bethesda, MD 20814-2762
Phone: (301) 347-9300 Fax: (301) 347-9310

Lecture Overview Although the majority of patients with CML respond well to imatinib, a minority of patients have relapsed. This part of the lecture will cover what has been learned about mechanisms of relapse and how this information has been translated into new therapies for patients with imatinib resistance. Although imatinib is a relatively specific inhibitor of the ABL kinase, a couple of other kinases, KIT and the platelet derived growth factor receptor are also inhibited by imatinib. This use of this information to treat successfully treat other malignant diseases driven by these kinases will be reviewed.	Part 2: Imatinib Resistance and Other Diseases Targeted by Imatinib (25:12) Click image above to start seminar in 320x240 format Click here to view in larger 640x480 format* QuickTime 7 Required 640x480 System Requirements (there may be a few seconds delay before seminars start) Downloads in alternative formats:* (To Save, Right Click a link below and select "Save Target/Link As") QuickTime (46mb) MP4 (294mb) iPod/iPhone Video (294mb) PowerPoint Slides 1/page (681kb) PowerPoint Slides 6/page (281kb) Format Descriptions Download Accelerator/Resume Broken Downloads Software
Part 1: Chronic Myeloid Leukemia (CML) and Imatinib (33:54) Part 3: Extending the Imatinib Paradigm (22:09) Speaker Bio Related Articles